VIIV HEALTHCARE PTY LTD

πŸ‡¦πŸ‡ΊAustralia
Ownership
-
Employees
-
Market Cap
-
Website

EuroSIDA As An External Comparator To MOTIVATE Trials

Completed
Conditions
Interventions
First Posted Date
2011-04-06
Last Posted Date
2011-05-16
Lead Sponsor
ViiV Healthcare
Target Recruit Count
1181
Registration Number
NCT01329783

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-04-04
Last Posted Date
2016-01-07
Lead Sponsor
ViiV Healthcare
Target Recruit Count
183
Registration Number
NCT01328041
Locations
πŸ‡ͺπŸ‡Έ

GSK Investigational Site, Sevilla, Spain

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-04-01
Last Posted Date
2017-12-06
Lead Sponsor
ViiV Healthcare
Target Recruit Count
138
Registration Number
NCT01327547
Locations
πŸ‡ΊπŸ‡Έ

AIDS Research Alliance, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Georgia Regents Medical Center, Augusta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Saint Michael's Medical Center, Newark, New Jersey, United States

and more 45 locations

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

First Posted Date
2011-02-04
Last Posted Date
2011-06-29
Lead Sponsor
ViiV Healthcare
Target Recruit Count
28
Registration Number
NCT01290211
Locations
πŸ‡§πŸ‡ͺ

Pfizer Investigational Site, Bruxelles, Belgium

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

First Posted Date
2011-01-25
Last Posted Date
2014-12-24
Lead Sponsor
ViiV Healthcare
Registration Number
NCT01283100
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Buffalo, New York, United States

Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-01-12
Last Posted Date
2014-03-03
Lead Sponsor
ViiV Healthcare
Target Recruit Count
98
Registration Number
NCT01275625
Locations
πŸ‡·πŸ‡Ί

Moscow regional center on AIDS and infectious diseases prophylaxis and control, Moscow, Russian Federation

πŸ‡·πŸ‡Ί

Federal State Institution Republican clinical infectious hospital of Roszdrav, Saint-Petersburg, Russian Federation

πŸ‡·πŸ‡Ί

Regional Center on AIDS and Infectious Diseases Prophylaxis and Control, Nizhnij Novgorod, Russian Federation

and more 4 locations

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

First Posted Date
2011-01-10
Last Posted Date
2014-05-19
Lead Sponsor
ViiV Healthcare
Registration Number
NCT01273103
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Madison, Wisconsin, United States

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

First Posted Date
2010-12-20
Last Posted Date
2018-04-04
Lead Sponsor
ViiV Healthcare
Target Recruit Count
844
Registration Number
NCT01263015
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, Tooting, London, United Kingdom

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

First Posted Date
2010-11-01
Last Posted Date
2022-03-15
Lead Sponsor
ViiV Healthcare
Target Recruit Count
724
Registration Number
NCT01231516
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, Tooting, London, United Kingdom

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

First Posted Date
2010-11-01
Last Posted Date
2017-06-08
Lead Sponsor
ViiV Healthcare
Target Recruit Count
27
Registration Number
NCT01231542
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Baltimore, Maryland, United States

Β© Copyright 2024. All Rights Reserved by MedPath